Semaglutide
A long-acting GLP-1 receptor agonist approved in injectable form for type 2 diabetes (Ozempic) and chronic weight management (Wegovy), and in oral form (Rybelsus). It is among the most extensively studied molecules in the peptide space.
Liraglutide
A once-daily GLP-1 receptor agonist approved for type 2 diabetes (Victoza) and, at a higher dose, for chronic weight management (Saxenda). It was the first GLP-1 agonist to secure a dedicated obesity indication.
Mechanism and pharmacology
Both are GLP-1 receptor agonists; the difference is engineering. Liraglutide is acylated for a half-life of roughly 13 hours and daily dosing. Semaglutide’s modifications extend its half-life to about a week, and an absorption-enhancer formulation makes an oral version possible.
Trial results
Liraglutide’s SCALE program reported roughly 8% weight reduction at 3.0 mg daily over 56 weeks. Semaglutide’s STEP 1 reported 14.9% at 2.4 mg weekly over 68 weeks. Cross-trial comparison has limits, but the magnitude difference is consistent with head-to-head-adjacent data.
Safety
Both share the GLP-1 class profile — gastrointestinal effects, gallbladder warnings, pancreatitis caution, and the medullary thyroid carcinoma/MEN2 contraindication. Liraglutide has a longer post-marketing record; semaglutide has a much larger current exposure database.
Practical differences
Weekly versus daily injection; an oral option versus none; different titration schedules and coverage landscapes. For a prescriber these are meaningful choices between two real medicines — a completely different situation from comparing research chemicals.
Why this comparison matters on an educational site
Because it shows what actual drug development looks like: measured human outcomes, labeled risks, and defined use — the standard against which every unapproved compound on this site should be judged.
Frequently Asked Questions
Is semaglutide just a better liraglutide?
For most studied populations the efficacy-tolerability balance favored semaglutide in trials, but "better" is a clinical judgment per patient — both remain legitimate approved medicines.
Can you switch between them?
Switching GLP-1 medicines is routine clinical practice managed by prescribers with titration plans — not something to arrange from a catalog.
Are the gray-market versions equivalent?
No. Compounded or unregulated copies of either bypass the manufacturing, storage, and dosing systems that make approved versions reliable.
Evidence tier: Approved medicine · Last reviewed: 2026-09-05 · Sources cited below.